These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15992094)

  • 1. Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.
    Geddes AM
    Expert Opin Investig Drugs; 1999 Apr; 8(4):487-505. PubMed ID: 15992094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection.
    Chodosh S
    Clin Microbiol Infect; 1998 Mar; 4 Suppl 1():S25-S31. PubMed ID: 11869247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B; Dutchman DA; Pettit R; Maroli A
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
    Chodosh S; Lakshminarayan S; Swarz H; Breisch S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE; Cranfield R; Breisch S; Pettit R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE; Zuck P; Vogel F; McIvor A; Peirzchala W; Smakal M; Staley H; Marr C
    J Antimicrob Chemother; 1999 Oct; 44(4):515-23. PubMed ID: 10588313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S; Swarz H; Breisch SA; Maroli AN
    Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM; Dever LL
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grepafloxacin: microbiological properties.
    Marriott MS
    Clin Microbiol Infect; 1998 Mar; 4 Suppl 1():S9-S14. PubMed ID: 11869244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grepafloxacin: pharmacokinetics and tissue penetration.
    Wise R
    Clin Microbiol Infect; 1998 Mar; 4 Suppl 1():S21-S24. PubMed ID: 11869246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.
    Langtry HD; Brogden RN
    Drugs; 1997 Jun; 53(6):973-1004. PubMed ID: 9179528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ
    J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.